Prostate Cancer Trial, Recruiting NCT06859203 Sponsor: Technical University of Munich Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06859203
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The person must be male and older than 18 years of age.
  • The person must have a history of localised prostate cancer (a specific type called adenocarcinoma) that was previously treated with the aim of curing it, and the cancer must now be showing signs of returning based on a blood marker called PSA, while still being hormone-sensitive.
  • The previous treatment must have included one or more of the following: surgical removal of the prostate (radical prostatectomy), surgical removal of the prostate followed by additional therapy, or radiation therapy and/or hormone-blocking therapy.
  • The person's PSA levels must meet specific thresholds depending on which treatment was received: after surgical removal of the prostate, the PSA must be 0.2 ng/mL or higher on two separate measurements, and fall between 0.2 and 2 ng/mL overall, with testing done at least 6 weeks after surgery; after radiation therapy as the primary treatment, the PSA must be at least 2 ng/mL above the lowest level it reached after treatment, and fall within the range of 2 to 4 ng/mL.

Who may not be able to join:

  • People who have any medical condition or situation that the trial doctor believes could affect the reliability of the study data or make it difficult to complete the study requirements (confirm with trial site).
  • People who are currently receiving, or have recently received within the last 3 months, hormone-blocking therapy — this includes surgical removal of the testicles, ongoing or intermittent hormone-suppressing injections or implants, or anti-androgen medications used alone or in combination with hormone-suppressing treatments.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Matthias Eiber, MD, Technical University of Munich

Phone: +49 89 4140 0

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Technical University of Munich
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Patient-level detection rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov